FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Penicillamine (Depen) Titratable Tablets
Status: Currently in Shortage
»Date first posted: 01/04/2018
»Therapeutic Categories: Endocrinology/Metabolism; Gastroenterology; Inborn Errors; Pediatric; Renal; Rheumatology

Expand all

Mylan Pharmaceuticals Inc. (Reverified 02/20/2019)

Company Contact Information:
800-796-9526

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Penicillamine tablets, 250 mg (NDC 0037-4401-01) Unavailable. Expected recovery for penicillamine tablets, 250 mg: Q2 2019 Other
D-PENAMINE (D-penicillamine) tablets, 125 mg tablets (NDC 0378-0709-01) Temporary importation is available Mylan in conjunction with FDA has initiated temporary importation of penicillamine tablets, 125 mg into the U.S. market to address drug shortage. Please see the Dear Health Care Provider Letter.

Dear Health Care Provider Letter

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English